



10 September 2019  
ASX Announcement

### **Retraction of Appendix 3B and 3Y**

Impression Healthcare Limited (“the Company”) wishes to advise that the Appendix 3B and Appendix 3Y released to ASX on 4 September 2019 in respect of securities issued to the Company’s CEO and Managing Director, Joel Latham, have been cancelled at this time due to an administrative oversight.

The issue of these securities requires shareholder approval and their issue last week prior to receiving such approval is a breach of ASX Listing Rule 10.14. As a result, these securities have now been cancelled and the Company intends on seeking shareholder approval for their issue as soon as practicable.

Attached is the a copy of the most recent previous Appendix 3B and 3Y - both lodged on 26 August 2019. A new Appendix 3B and Appendix 3Y will be issued by the Company following the approval and subsequent re-issue of these securities.

The Company wishes to apologise for this error and has revised its ASX announcements and governance procedures to reduce the risk of such an oversight occurring in the future.

Glenn Fowles  
COMPANY SECRETARY

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

**Impression Healthcare Limited**

ABN

93 096 635 246

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- |   |   |  |
|---|---|--|
| 1 | +Class of +securities issued or to be issued  | (1) Ordinary fully paid shares<br>(2) Unlisted options   |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued   | (1) 16,575,426<br>(2) 75,368,422   |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | (1) Listed IHL ordinary fully paid shares<br>(2) Unlisted options: <ul style="list-style-type: none"> <li>a) 55,368,422 with \$0.08 strike price and expiry date of 30 September 2021</li> <li>b) 10,000,000 with \$0.02 strike price and expiry of 1 January 2020</li> <li>c) 10,000,000 with \$0.03 strike price and expiry of 1 May 2020</li> </ul> |

<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>(1) Yes</p> <p>(2) These three series of options are a new class of securities not previously on issue</p>
<p>5 Issue price or consideration</p>	<p>(1) 16,575,426 IHL ordinary shares issued for \$0.038 per share (\$629,866)</p> <p>(2) (a) (i) 22,368,422 \$0.08/30-Sep-21 options issued for nil (\$0)</p> <p>(a) (ii) 33,000,000 \$0.08/30-Sep-21 options issued for \$0.00001 each (\$330)</p> <p>(b) 10,000,000 \$0.02/01-Jan-20 options issued for nil (\$0)</p> <p>(c) 10,000,000 \$0.03/01-May-2020 options issued for nil (\$0)</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>(1)(a) 16,574,426 IHL ordinary shares issued in respect of placement announcements made on 3 July 2019 and 9 July 2019 and approved by shareholders on 9 August 2019.</p> <p>(1)(b) 1,000 IHL ordinary shares issued under prospectus dated 22 August 2019</p> <p>(2)(a) \$0.08/30-Sep-21 options issued in respect of placement announcements made on 3 July 2019 and 9 July 2019 and approved for issue by shareholders on 9 August 2019.</p> <p>(2)(b) \$0.02/01-Jan-20 options and (2)(c) \$0.03 01-May-20 options issued in respect of announcement made on 21 March 2019 and approved for issue by shareholders on 9 August 2019.</p>

6a	<p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the +securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	Yes
6b	The date the security holder resolution under rule 7.1A was passed	22 November 2018
6c	Number of +securities issued without security holder approval under rule 7.1	1,000
6d	Number of +securities issued with security holder approval under rule 7.1A	Not applicable
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable
6f	Number of +securities issued under an exception in rule 7.2	Not applicable
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	Not applicable
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 – 19,380,123 7.1A – 24,741,821 – refer Annexure 1

7      <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

(1)(a) 23 August 2019 (16,574,426 Ord IHL)
(1)(b) 26 August 2019 (1,000 Ord IHL))
(2) 23 August 2019 (all options the subject of this notice)

8      Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX (including the <sup>+</sup> securities in section 2 if applicable)	Number	<sup>+</sup> Class
	633,056,936	Ord Fully Paid (IHL)
	262,360,728	30-Sep-2020 \$0.04 Options (IHLOB)

9      Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX (including the <sup>+</sup> securities in section 2 if applicable)	10,000,000	Unquoted \$0.02 01-Jan-2020 options
	10,000,000	Unquoted \$0.03 01-May-2020 options
	55,368,422	Unquoted \$0.08 30-Sep-2021 options
	20,000,002	Unquoted restricted Class B Performance shares
	24,166,668	Unquoted restricted Performance Rights

10      Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Only fully paid ordinary shares are eligible for dividends
--	--

Part 2 - Pro rata issue

- |   |                |
|---|----------------|
| 11      Is security holder approval required?                               | Not applicable |
| 12      Is the issue renounceable or non-renounceable?                      | Not applicable |
| 13      Ratio in which the <sup>+</sup> securities will be offered          | Not applicable |
| 14 <sup>+</sup> Class of <sup>+</sup> securities to which the offer relates | Not applicable |
| 15 <sup>+</sup> Record date to determine entitlements                       | Not applicable |

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
17	Policy for deciding entitlements in relation to fractions	Not applicable
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	Not applicable
19	Closing date for receipt of acceptances or renunciations	Not applicable
20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable

---

29	Date rights trading will end (if applicable)	Not applicable
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable
33	<sup>+</sup> Issue date	Not applicable

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities  
(tick one)

(a)  +Securities described in Part 1

(b)  All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Questions 35 to 42 are Not Applicable

Tick to indicate you are providing the information or documents

35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities



**Entities that have ticked box 34(b)**

38 Number of +securities for which +quotation is sought

39 +Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)		

## Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



Date: 26 August 2019

Print name: Glenn Fowles  
Company Secretary

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	288,288,248
<p><b>Add</b> the following:</p> <ul style="list-style-type: none"> <li>• Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	<p style="text-align: right;">6,000,000 (Issue of shares approved by shareholder meeting 22 Aug 2018)</p> <p style="text-align: right;">33,117,189 (allotment of rights issue – Oct18)</p> <p style="text-align: right;">40,454,873 (allotment of rights shortfall – Oct18)</p> <p style="text-align: right;">156,000,000 (approval by shareholders at AGM – 20 Nov 2018 – conversion securities and placement)</p> <p style="text-align: right;">48,557,896 - approved by shareholders at EGM – 09 August 2019</p>
<b>Subtract</b> the number of fully paid +ordinary securities cancelled during that 12 month period	0
<b>“A”</b>	572,418,206

<b>Step 2: Calculate 15% of “A”</b>	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A”</b> by 0.15	85,862,731
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	16,800,000 ordinary shares (Sep18) 13,100,000 IHLOB options (Sep18) 1,000,000 performance rights (Sep18) 13,177,210 IHLOB options (Nov18) 3,034,312 IHL ordinary shares (Nov18) 600,000 IHL ordinary shares (Jan19) 6,500,000 IHLOB options (Jan19) 9,269,086 IHL ordinary shares (Apr19) 1,000,000 IHLOB options (Apr19) 2,001,000 IHL ordinary shares (Jul19) 1,000 IHL ordinary shares (This App 3B)
“C”	<b>66,482,608</b>
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
“A” x 0.15  <i>Note: number must be same as shown in Step 2</i>	85,862,731
<b>Subtract “C”</b>  <i>Note: number must be same as shown in Step 3</i>	66,482,608
<b>Total</b> [“A” x 0.15] – “C”	<b>19,380,123</b>  <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b>  <i>Note: number must be same as shown in Step 1 of Part 1</i>	572,418,207
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10  <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	57,241,821
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	29,000,000 performance rights (Sep18)  3,500,000 IHL ordinary shares (Jan19)
<b>“E”</b>	<b>32,500,000</b>

**Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A**

<p>“A” x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	<p>57,241,821</p>
<p><b>Subtract “E”</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	<p>32,500,000</p>
<p><b>Total</b> [“A” x 0.10] – “E”</p>	<p><b>24,741,821</b></p> <p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

# Appendix 3Y

## Change of Director's Interest Notice

<b>Name of entity</b>	<b>Impression Healthcare Limited</b>
<b>ACN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Joel LATHAM
<b>Date of last notice</b>	29 July 2019

### Part 1 - Change of director's relevant interests in securities

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest</b>	n/a
<b>Date of change</b>	23 August 2019
<b>No. and class of securities held prior to change</b>	<ul style="list-style-type: none"> <li>• 9,845,795 IHL ordinary shares</li> <li>• 4,237,500 IHLOB options</li> <li>• 6,000,000 unlisted performance rights</li> </ul>
<b>Number and class of securities acquired</b>	400,000 IHL Ordinary shares; and 200,000 unlisted \$0.08 Options expiry 30-Sep-21
<b>Number and class of securities disposed</b>	Nil
<b>Value/Consideration</b>	\$15,200
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1) 10,245,795 IHL ordinary shares</li> <li>2) 4,237,500 IHLOB options</li> <li>3) 6,000,000 unlisted performance rights</li> <li>4) 200,000 unlisted \$0.08 Options expiry 30-Sep-21</li> </ol>
<b>Nature of change</b>	Participation in placement

### Part 2 – Change of director's interests in contracts

Not Applicable

### Part 3 – Closed period

<b>Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a